ChemicalBook > CAS DataBase List > Goserelin

Goserelin

Goserelin Structure
Goserelin
  • CAS No.65807-02-5
  • Chemical Name:Goserelin
  • CBNumber:CB4281027
  • Molecular Formula:C59H84N18O14
  • Formula Weight:1269.41
  • MOL File:65807-02-5.mol
Goserelin Property
  • Density 1.50±0.1 g/cm3(Predicted)
  • storage temp. −20°C
  • solubility H2O: 20 mg/mL, clear, colorless
  • form white powder
  • pka 9.82±0.15(Predicted)
  • InChIKey BLCLNMBMMGCOAS-URPVMXJPSA-N
  • NCI Dictionary of Cancer Terms Zoladex
  • FDA UNII 0F65R8P09N
  • NCI Drug Dictionary Zoladex
  • ATC code L02AE03
Safety
Hazard and Precautionary Statements (GHS)
  • Symbol(GHS)
  • Signal wordDanger
  • Hazard statements H334-H332-H317
  • Precautionary statements P261-P272-P280-P302+P352-P333+P313-P321-P363-P501-P261-P285-P304+P341-P342+P311-P501-P261-P271-P304+P340-P312

Goserelin Chemical Properties,Usage,Production

  • Description Goserelin is an analog of luteinizing hormone-releasing hormone (LHRH) useful in the treatment of malignancies responsive to hormonal manipulation. Administered parenterally in a biodegradable depot, goserelin is reportedly as effective as orchidectomy and oophorectomy in patients with advanced prostate carcinoma and pre-menopausal breast cancer.
  • Chemical Properties White or almost white powder.
  • Originator ICI (United Kingdom)
  • Uses Labeled Goserelin, intended for use as an internal standard for the quantification of Goserelin by GC- or LC-mass spectrometry.
  • Uses Labelled Goserelin (G767500). Synthetic peptide agonist analog of LH-RH. Antineoplastic (hormonal).
  • Uses Goserelin USP (Zoladex) is used to treat Prostatic carcinoma.
  • Definition ChEBI: Goserelin is an organic molecular entity.
  • Manufacturing Process (a) Solid Phase Preparation of Nonapeptide
    The solid phase synthesis was carried out in automatic mode on an Applied Biosystems 430A Peptide Synthesizer using Boc-Pro-OBzl-polystyrene resin 1% cross-linked with divinylbenzene (Peninsula Laboratories), 1.25 g, 0.38 meq/g though nominally 0.7 meq/g). The following protected amino acids were converted to benzotriazolyl esters by reaction with HOBt (1- hydroxybenzotriasole) and DIPC (di-isopropylcarbodiimide) in DMF immediately before use. The protected amino acids were coupled in the following sequence: Boc-Arg(HCl)-OH; Boc-Leu-OH; Fmoc-D-Ser(But)-OH; Fmoc-Tyr(BrZ)-OH; Fmoc-Ser-OH; Fmoc-Trp-OH; Fmoc-His(Fmoc)-OH; PyrOH. The sequence of operations for the first two stages (using Boc-protectedamino acids) was: removal of Boc with 45% triflouroacetic acid in dichloromethane;10% DIEA (diethyl amine)/DMF wash; coupling (2 equivalents of protected amino acid HOBt ester); removal of Boc as above. The sequence of operations for the last six stages (using Fmoc-protectedamino acids) was: removal of Fmoc with 20% piperidine/DMF; 0.5 molar HOBt/DMF wash; coupling (1 equivalent of protected amino acid HOBt ester). All coupling reactions except that using Boc-Arg(HCl)-OH were of 1 hour duration; the Boc-Arg(HCl)-OH one was of 2 hours duration. There was thus obtained the nonapeptide-resin (1.7 g; 0.29 mmole peptide per g) with the Tyr still protected by BrZ.
    (b) Cleavage of Peptide From Resin
    The peptide resin prepared above was treated with a 20-fold excess of anhydrous hydrazine in DMF (20 ml) at laboratory temperature for 24 hours, and the mixture was filtered and evaporated to dryness. This procedure also removed the BrZ protecting group from the Tyr moeity. The residue was purified by gel filtration on a column (LH 20 Sephadex) using a 20:1 v/v mixture of water and acetic acid as eluant. There was thus obtained Pyr-HisTrp-Ser-Tyr-D-Ser(But)-Leu-Arg(H+)-Pro-NH-NH2. The structure of which was confirmed by amino acid analysis and mass spectroscopy.
    (c) Preparation of Goserelin
    A solution of potassium cyanate (11 mg) in water (1.36 ml) was added portionwise during 1 hour to a solution of the above hydrazide (118 mg) in a 20:1 v/v mixture of water and acetic acid (10 ml). The mixture was freezedried and the residue was purified by reverse-phase column chromatography (Dynamax 60 ANG, C18, 1 inch diameter) using a gradient of 10% to 40% by volume of acetonitrile in water containing 0.1% trifluoroacetic acid. There was thus obtained goserelin (100 mg, 25% yield overall), the structure of which was confirmed by mass spectroscopy.
  • brand name Zoladex (Zeneca).
  • Therapeutic Function Antineoplastic, Antitumor
  • Clinical Use Synthetic decapeptide analogue of LHRH:

    Treatment of advanced prostate cancer, breast cancer, endometriosis and endometrial thinning and uterine fibroids
  • Side effects Hot flashes (flushing), dizziness, headache, increased sweating, decreased sexual interest/ability, trouble sleeping, nausea, change in breast size, vaginal dryness, or hair loss may occur. Pain, bruising, bleeding, redness, or swelling at the injection site may also occur.
    This medication may rarely make your blood sugar rise, which can cause or worsen diabetes.
    Serious side effects including: symptoms of a heart attack (such as chest/jaw/left arm pain, shortness of breath, unusual sweating), signs of a stroke (such as weakness on one side of the body, trouble speaking, sudden vision changes, confusion), fast/irregular heartbeat, severe dizziness, fainting.
    In men using this medication for prostate cancer, a rare but very serious urinary blockage problem or spinal cord problem (compression) can occur, especially during the first month of treatment.
  • Drug interactions Goserelin may be given on its own or is often combined with another hormone therapy such as tamoxifen or drugs known as aromatase inhibitors (anastrozole, exemestane and letrozole).
    The risk or severity of QTc prolongation can be increased when Goserelin is combined with Clozapine. The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Cocaine.
  • Metabolism Metabolised by tissue peptidases and is excreted in urine and bile as unchanged drug and metabolites.
Goserelin Preparation Products And Raw materials
Raw materials
Preparation Products
Goserelin Suppliers
Global(160)Suppliers
  • Supplier：
    Cellmano Biotech Limited
  • Tel：0551-65326643<br/>18156095617
  • Email：info@cellmano.com
  • Country：China
  • ProdList：995
  • Advantage：58
  • Supplier：
    career henan chemical co
  • Tel：+86-0371-86658258<br/>+8613203830695
  • Email：factory@coreychem.com
  • Country：China
  • ProdList：29808
  • Advantage：58
Goserelin Spectrum
65807-02-5, GoserelinRelated Search:
  • hormones
  • peptides
  • Pepetides
  • 多肽
  • 标准品
  • 优势产品
  • 肽类
  • 医药原料药
  • 生物制药
  • 医药原料
  • 药物
  • 抗肿瘤药
  • 抗代谢物抗肿瘤药物
  • C59H84N18O14
  • 145781-95-6
  • 戈舍瑞林-D7三氟乙酸盐
  • 戈舍瑞林(GOSERELIN)
  • 戈舍瑞林-D7
  • 戈舍瑞林NMR鉴定 EP标准品
  • 戈舍瑞林 EP标准品
  • 醋酸戈舍瑞林 EP标准品
  • 戈舍瑞林中间体
  • 戈舍瑞林杂质D7
  • 3-[焦谷氨酰组氨酰色氨酰丝氨酰醋氨酰(3-O-叔丁基)-D丝氨酰亮氨酰精氨酰脯氨酰]肼基甲酰胺
  • 胺碘酮盐酸盐杂质E
  • 性瑞林
  • 果丝瑞宁
  • 戈舍瑞林
  • 高舍瑞林
  • 戈舍瑞林-D5
  • 65807-02-5
  • Goserelin-d7 Tritrifluoroacetate
  • endo-5a-glycine-gonadorelin
  • Gosereline
  • Goserelin validation mixture CRS
  • Goserlin
  • Zoladex
  • Goserelin Acetate(net)
  • Goserelin-d7Q: What is Goserelin-d7 Q: What is the CAS Number of Goserelin-d7
  • Goserelin D10Q: What is Goserelin D10 Q: What is the CAS Number of Goserelin D10 Q: What is the storage condition of Goserelin D10 Q: What are the applications of Goserelin D10
  • Goserelin Deuterated Acetate DISCONTINUED
  • Goserelin USP/EP/BP
  • Goserelin/Zoladex/Decapeptide I
  • Goserelin CRS
  • Goserelin for NMR identification CRS
  • Goserelin, Gosereline, Goserelinum, Goserelina
  • Geserelin
  • Goserelin-d7
  • Human Goserelin
  • GOSERELIN ACETATE PH. EUR.
  • Goserelin (free base)
  • (D-Ser(tBu)6,Azagly10)-LHRH (free base)
  • Pyr-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-Azagly-Gly-NH2
  • Sodium alpha-(3,5-dibromo-2-methyl-4-oxo-2,5-cyclohexadienylidene)-alpha-(3,5-dibromo-4-hydroxyphenyl)toluenesulphonate
  • Phenol, 4,4'-(2,2-dioxido-3H-1,2-benzoxathiol-3-ylidene)bis(2,6-dibromo-3-methyl-, sodium salt (1:1)
  • Pbtbo
  • Einecs 263-657-4
  • 5-Oxo-L-Pro-L-His-L-Trp-L-Ser-L-Tyr-O-(1,1-dimethylethyl)-D-Ser-L-Leu-L-Arg-L-Pro-ureido-NH2

Home

My